Strategic emerging industry pharmaceutical special funds will be expected to be issued during the year

Director Yao Yao of the Planning Department of the Ministry of Industry and Information Technology stated on the 23rd that during the “12th Five-Year Plan” period, China will increase financial and financial support for the biomedical industry, and the strategic emerging industry pharmaceutical special funds are expected to be decentralized during the year.

Yao Hao introduced that the funds were decentralized from this year and the interval was once a year. Chemical new drugs and biotechnology drugs are the two major supporting directions for strategic emerging industries and pharmaceutical special funds. Pharmaceutical companies may apply for funding from the local economic and trade committees, development and reform committees and financial departments.

He said that in addition to the strategic emerging industry special funds, China will also expand financial and taxation financial support for bio-pharmaceutical companies from the three major aspects of major new drug creation projects, plus deductions for R&D investment and other tax policies and capital markets during the “12th Five-Year Plan” period. . In particular, it will increase the implementation of tax incentives for biomedical companies. Through venture capital funds, equity investment funds, venture capital funds, GEM, and small and medium-sized board markets, they provide support to the biopharmaceutical industry and enterprises.

Yao Hao said that medical equipment will be another key industry in China's future remanufacturing field. At present, China's pilot remanufacturing products are mainly concentrated in the auto parts and household appliances industry.